Mepenzolate bromide


Full Prescribing Info
Dosage/Direction for Use

Oral
Adjunct in peptic ulcer
Adult: 25-50 mg 4 times daily, titrated to the lowest effective dose and adjust accordingly to patient's response.
Administration
Should be taken with food.
Contraindications
Hypersentivity. Glaucoma, obstructive uropathy and GI disease, paralytic ileus, myasthenia gravis, unstable CV status in acute GI haemorrhage, intestinal atony, toxic megacolon complicating ulcerative colitis.
Special Precautions
Patient w/ autonomic neuropathy, ulcerative colitis, CV disease (e.g. coronary heart disease, CHF, cardiac arrhythmias, tachycardia, HTN), prostatic hypertrophy, hyperthyroidism. Renal and hepatic environment. Elderly, debilitated patients. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness and blurred vision, if affected, do not drive or operate machinery.
Adverse Reactions
Significant: Drowsiness, blurred vision, diarrhoea, heat prostration, psyschosis. Nervous: Dizziness, headache, nervousness, confusion, insomnia, weakness. CV: Tachycardia, palpitations. GI: Vomiting, nausea, constipation, ageusia, bloating, xerostomia. Endocrine: Decreased lactation. Genitourinary: Urinary retention, urinary hesitancy, impotence. Ophthalmologic: Increased ocular tension, cycloplegia, mydriasis. Dermatologic: Urticaria, hypohidrosis.
Potentially Fatal: Anaphylaxis.
Overdosage
Symptoms: Curare-like effects (e.g. neuromuscular blockade leading to weakness and possible paralysis), headache, nausea, vomiting, blurred vision, mydriasis, hot and dry skin, xerostomia, difficulty in swallowing, dizziness, CNS stimulation. Management: Employ gastric lavage, admin of emetics and activated charcoal. May use sedatives (e.g. short-acting barbiturates, benzodiazepines) for overt signs of excitement. If indicated, may also use parenteral cholinergic agent as antidote.
Drug Interactions
May increase adverse effects of other anticholinergic drugs (e.g. amantadine, class I antiarrhythmic agents, antihistamines, antipsychotic agents, benzodiazepines, MAOIs, narcotic analgesics, nitrates and nitrites, sympathomimetic agents, TCA). May antagonise effects of antiglaucoma agents and drugs which alter GI motility (e.g. metoclopramide). Increased serum digoxin concentration and toxicity.
Action
Mepenzolate bromide is an antimuscarinic agent and a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses colon contraction.
Absorption: Incompletely absorbed from the GI tract.
Excretion: Via urine (3-22%) and faeces.
Storage
Oral: Store below 30°C. Protect from heat.
Disclaimer: This information is independently developed by CIMS based on mepenzolate bromide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in